| |
Company
[ News ] [ Our People ] [ Our Partners ]
Our People
[ Management Team ] [ Scientific Advisors ] [ Board of Directors ]
Management Team
 Erich
Mohr, Ph.D., R.Psych.
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.
Erich Mohr, Ph.D., R.Psych, is the Chairman and CEO of MedGenesis
Therapeutix Inc. which he founded in 2005. Dr. Mohr, a Professor of
Medicine and Psychology at the University of Ottawa until 1997 has over
21 years of experience in experimental therapeutics of CNS disorders. He
is credited with over 150 publications, books, book chapters and
abstracts and has edited the Handbook of Clinical Trials: The
neurobehavioral approach. Dr. Mohr has chaired and/or served on several
regulatory advisory panels for the approval of new products for the
treatment of neurodegenerative disease and is the former Chairman and
Chief Executive Officer of CroMedica Global Inc. (merged with PRA
International in 2002) and the co-founder of several biotechnology
companies. His most recent position was with PRA International, where he
served as Chief Scientific Officer. PRA is one of the top 5 contract
research organizations in the world and is listed on NASDAQ. Over the
course of his career, Dr. Mohr has overseen and/or participated in
dozens of clinical development programs resulting in a number of
approved drugs.
 Greg
A. Johnson
Chief Operating Officer
Mr. Johnson has 17 years of clinical research experience, and is a
recognized expert in electronic data capture and the implementation and
use of computerized systems in a clinical research setting. Before
joining MedGenesis, Mr. Johnson held several senior positions at PRA
International including Vice President, Operations for the Americas, and
Vice President, Global Data Management. During his tenure at PRA
International, he was responsible for the successful management of
dozens of global clinical programs in several therapeutic areas. In
addition to his expertise in clinical data management, Mr. Johnson has
wide-ranging experience in strategic planning, project management and
operations management. Mr. Johnson has a M.Sc. in Clinical Research,
holds Project Management Professional (PMP) certification, and is a
Fellow in the Institute of Clinical Research (FICR).
 Michael Lincoln
Chief Financial Officer
Mr. Michael Lincoln has over 21 years of experience in the
pharmaceutical and biotechnology industries with a proven track record
of successfully managing the growth and development of biotech companies
and creating partnerships. Previous experience includes being the Chief
Financial Officer of a public biotech company and participation in the
Initial Public Offering and the raising of over $20 MM in capital. In
addition, Mr. Lincoln has initiated and participated in the completion
of multiple partnerships including a technology partnership with a large
multinational, M&A activity, joint ventures, and the licensing of
numerous branded products. Prior to joining MedGenesis, Mr. Lincoln was
a Senior Executive at Transition Therapeutics Inc. and the Altimed
Pharmaceutical Company and has held various management positions at
Merck Frosst Canada Inc. He is a co-founder and past Chair of the
Canadian Healthcare Licensing Association and has a Master of Business
Administration degree and is a Certified Management Accountant.
 Matthias
Luz, M.D.
Chief Medical Officer
Dr. Luz is a board-certified anesthesiologist and intensive care physician with
an extensive background in epidemiology, clinical trial methodology and global
regulatory affairs. In addition to six years of clinical experience, Dr. Luz has
17 years of global product development experience in the biopharmaceutical and
clinical research industry. Before joining MedGenesis, Dr. Luz was
the Vice President and Head, Global Product Development Services for PRA
International. In this capacity, Dr. Luz led a worldwide team of senior
scientists and accomplished drug development experts involved in the design and
implementation of high quality development programs from pre-IND to Phase III
and submission. During a previous tenure at Behringwerke/Hoechst Marion Roussel/Aventis,
Dr. Luz led the team that brought Refludan®, the first therapeutic for
heparin-induced thrombocytopenia, to market worldwide. Dr. Luz also held other
senior positions at Knoll/Abbott and Cardion.
 Lara Krupka-Longpre
Senior Vice President, Clinical & Corporate Affairs
Ms. Krupka-Longpre has 15 years of clinical research experience in numerous
roles in a CRO environment. Prior to joining MedGenesis, Ms. Krupka-Longpre held senior
positions at PRA International including Vice President of Proposals &
Contracts, Vice-President of Quality and Process Management, Director of
Global Regulatory Affairs, and Director of Operations. Areas of specific
expertise include project management, clinical operations, and quality
management systems. Ms. Krupka-Longpre has an MBA, and a M.Sc. in Medical
Science.
Page last updated:
29 June 2010
|
|
